Mendelow A D, Stockdill G, Steers A J, Hayes J, Gillingham F J
Acta Neurochir (Wien). 1982;62(3-4):195-202. doi: 10.1007/BF01403624.
Antifibrinolytic agents have been claimed to reduce the rebleed rate in patients with subarachnoid haemorrhage from intracranial aneurysms. However, these agents may in themselves increase the incidence of delayed cerebral ischaemia in these patients. We have used aspirin in an attempt to reduce the incidence of this complication. In a prospective, double-blind trial of aspirin against placebo, 53 patients with subarachnoid haemorrhage were all treated with the antifibrinolytic agent tranexamic acid. Twenty-seven patients received aspirin and 26 patients received placebo. The morbidity and mortality was similar in each group. A further breakdown into patients who had their aneurysms clipped at craniotomy (21 patients) similarly failed to show a more favourable outcome in either group. It is concluded that aspirin does not affect the outcome in patients with subarachnoid haemorrhage treated with tranexamic acid.
抗纤溶药物据称可降低颅内动脉瘤所致蛛网膜下腔出血患者的再出血率。然而，这些药物本身可能会增加此类患者迟发性脑缺血的发生率。我们使用阿司匹林试图降低这种并发症的发生率。在一项阿司匹林与安慰剂对比的前瞻性双盲试验中，53例蛛网膜下腔出血患者均接受了抗纤溶药物氨甲环酸治疗。27例患者接受阿司匹林治疗，26例患者接受安慰剂治疗。每组的发病率和死亡率相似。对在开颅手术中夹闭动脉瘤的患者（21例）进一步细分，同样未显示出两组中有更有利的结果。得出的结论是，阿司匹林对接受氨甲环酸治疗的蛛网膜下腔出血患者的预后没有影响。
